Loading...
CFOR logo

CapForce Inc.OTCPK:CFOR Stock Report

Market Cap US$52.7m
Share Price
n/a
1Y4,249,900.0%
7D-17.5%
1D-7.6%
Portfolio Value
​
View

CapForce Inc.

OTCPK:CFOR Stock Report

Market Cap: US$52.7m

CapForce (CFOR) Stock Overview

Operates as a capital markets advisory and financial technology company. More details

CFOR fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance4/6
Financial Health5/6
Dividends0/6

Rewards

Price-To-Earnings ratio (0.9x) is below the US market (18.4x)

Earnings grew by 293.9% over the past year

Risk Analysis

Highly volatile share price over the past 3 months compared to the US market

High level of non-cash earnings

Does not have a meaningful market cap ($53M)

Shareholders have been diluted in the past year

+ 1 more risk

CFOR Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW440,300 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.
Grow your followingReal investors. The kind who actually invest, not scroll past.
Unlock free accessFree premium subscription for consistent and quality authors.
Learn moreCreate Narrative
B
BlackGoat
R
RockeTeller
I
Investingwilly
D
davidlsander
440,300 investors already sharing narratives
View all narratives

CapForce Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for CapForce
Historical stock prices
Current Share PriceUS$4.25
52 Week HighUS$34.00
52 Week LowUS$0.0001
Beta-2623.48
1 Month Change13.33%
3 Month Change112.50%
1 Year Change4,249,900.00%
3 Year Change86.40%
5 Year Change-99.35%
Change since IPO-99.90%

Recent News & Updates

Recent updates

Seeking Alpha • Sep 30

OpGen to raise $3.38M in direct stock offering

OpGen (NASDAQ:OPGN) announced Friday it has signed a $3.38M securities purchase deal with a single institutional investor. It includes the the direct offering of 9,660,000 shares of OpGen (OPGN), 33,810 shares of its Series C mirroring preferred stock, and warrants to purchase up to same number of shares, at a combined purchase price of $0.35 each. Warrants have an exercise price of $0.377 per share and and will expire in five and one-half years. The management said, "the company intends to use the net proceeds to (i) continue commercialization of the FDA-cleared Acuitas AMR Gene Panel test for isolates in the U.S.; (ii) commercialize our other products with a focus on the Unyvero platform and diagnostic tests; (iii) support further development and commercialization of the Ares Genetics database; among other investments" Closing of the offering is expected on Oct. 3, 2022. OPGN shares are down 14% in pre-market on Friday. Earlier: OpGen's subsidiary signs R&D agreement with FIND
Seeking Alpha • Sep 20

OpGen's subsidiary signs R&D agreement with FIND

OpGen's (NASDAQ:OPGN) German subsidiary Curetis has signed an R&D collaboration agreement with global diagnostics alliance FIND. The collaboration is focused on demonstrating the capabilities of OpGen's Unyvero A30 RQ platform for use in low and middle income countries for rapid detection of antimicrobial resistance (AMR). During the anticipated feasibility project, Curetis' R&D team will strive to develop a molecular test panel with a comprehensive set of pathogen ID and AMR detection assays, develop an easy to perform workflow compatible with available blood culture systems in target regions and to adapt some key features of the A30 RQ platform important for use in environments often found in LMICs. If successful, both parties have agreed to discuss the option of a potential future collaboration and commercialization agreement. Such future collaboration agreement would aim to bring the Unyvero A30 RQ platform and initial application products through required clinical studies and regulatory approvals in LMICs to make them commercially available at an attractive cost profile to commercial distribution partners. OPGN shares have gained 9% pre-market
Seeking Alpha • Aug 31

Nasdaq grants extension to OpGen to regain compliance with minimum bid price requirement

The Nasdaq has granted to the medicine company OpGen (NASDAQ:OPGN) a 180-day extension to regain compliance with the stock exchange's minimum bid price requirement. OpGen now has until Feb. 27, 2023, to regain compliance. The compliance will be regained if at any time until Feb. 27, 2023, the bid price per share closes at or above $1.00 for a minimum of 10 consecutive trading days. OPGN shares were trading -0.60% pre-market. Source: Press Release
Seeking Alpha • Aug 25

OpGen launches sequencing services for infectious diseases in US

OpGen (NASDAQ:OPGN) said it launched next generation sequencing  services in the U.S. for use infectious diseases. The services, which are developed by OpGen's unit Ares Genetics, will provide the infectious disease community in the U.S. with routine sequencing of priority isolates and outbreak analyses that support their needs for surveillance, infection prevention and antibiotic stewardship, the company OpGen noted that the Rockville-based laboratory's services at launch include rapid turnaround sequencing of clinical isolates, differentiated interpretative services and a web application called AREScloud for outbreak analysis.
Seeking Alpha • Aug 11

OpGen GAAP EPS of -$0.13 beats by $0.02, revenue of $1M in-line

OpGen press release (NASDAQ:OPGN): Q2 GAAP EPS of -$0.13 beats by $0.02. Revenue of $1M (+23.5% Y/Y) in-line.
Seeking Alpha • Jul 08

OpGen reports preliminary revenue estimate for Q2 2022

OpGen (NASDAQ:OPGN) announced Friday the preliminary second quarter estimates with revenue expected to be $1M, up from $0.8M in prior year. "We are excited by the progress made in the second quarter, especially the fact that in June we signed the first commercial contract for our Acuitas AMR Gene Panel in the U.S. with a major hospital in the Northeast, the expansion of our distribution partnership with Menarini with significantly increased annual minimum revenue commitments by Menarini along with the agreement whereby Menarini has purchased the entire European pool of Unyvero systems across 9 countries from us at residual fair market value," stated President and CEO Oliver Schacht.  Cash as of June 30, 2022 was approximately $16.6M.

Shareholder Returns

CFORUS BiotechsUS Market
7D-17.5%-5.3%-1.0%
1Y4,249,900.0%37.0%14.1%

Return vs Industry: CFOR exceeded the US Biotechs industry which returned 37% over the past year.

Return vs Market: CFOR exceeded the US Market which returned 14.1% over the past year.

Price Volatility

Is CFOR's price volatile compared to industry and market?
CFOR volatility
CFOR Average Weekly Movement155.8%
Biotechs Industry Average Movement9.6%
Market Average Movement6.9%
10% most volatile stocks in US Market15.3%
10% least volatile stocks in US Market2.9%

Stable Share Price: CFOR's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: CFOR's weekly volatility has decreased from 243424% to 156% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
20013Christian-Laurent Bontewww.capforce.inc

CapForce Inc. operates as a capital markets advisory and financial technology company. The company offers services including listing consultancy, sponsorship services, and operates the CapForce EC platform. CapForce Inc. was formerly known as OpGen, Inc. and changed its name to CapForce Inc. in February 2026.

CapForce Inc. Fundamentals Summary

How do CapForce's earnings and revenue compare to its market cap?
CFOR fundamental statistics
Market capUS$52.69m
Earnings (TTM)US$61.95m
Revenue (TTM)US$76.20m
0.9x
P/E Ratio
0.7x
P/S Ratio

Is CFOR overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
CFOR income statement (TTM)
RevenueUS$76.20m
Cost of RevenueUS$8.02m
Gross ProfitUS$68.18m
Other ExpensesUS$6.23m
EarningsUS$61.95m

Last Reported Earnings

Jun 30, 2026

Next Earnings Date

n/a

Earnings per share (EPS)5.00
Gross Margin89.48%
Net Profit Margin81.30%
Debt/Equity Ratio0.3%

How did CFOR perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/09/13 02:48
End of Day Share Price 2026/09/11 00:00
Earnings2026/06/30
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CapForce Inc. is covered by 5 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Benjamin HaynorAlliance Global Partners
null nullBrookline Capital Markets
Nidhi SinghEdison Investment Research